Machine learning in drug discovery, along with artificial intelligence, is transforming the pharmaceutical industry by accelerating the development of new treatments.
Historically, the process of discovering and developing new drugs has been painstakingly slow, fraught with high failure rates and incredibly expensive. However, new developments in AI-driven methodologies, particularly in digital chemistry and biology, are creating unprecedented opportunities to accelerate drug discovery, according to Stephen Mackinnon (pictured), vice president of applied machine learning at Recursion Pharmaceuticals Inc.
“Machine learning helps us understand more about the world. It helps us understand more about biology so that when we take that risk, when we go through that grand experiment of a clinical trial,” he said. “We’re better equipped with knowledge of what that drug is doing, what that drug is doing to the system, what the drug is doing to the body so that we can make a more informed decision as what goes through.”
Mackinnon spoke with theCUBE Research’s …